guest ::
| Home > Publications database > Haematotoxicity of Craniospinal Radiochemotherapy for Metastatic Paediatric High-Grade Glioma. > print |
| Home > Publications database > Haematotoxicity of Craniospinal Radiochemotherapy for Metastatic Paediatric High-Grade Glioma. > print |
| 001 | 305734 | ||
| 005 | 20251112115732.0 | ||
| 024 | 7 | _ | |a 10.1016/j.clon.2025.103956 |2 doi |
| 024 | 7 | _ | |a pmid:41207064 |2 pmid |
| 024 | 7 | _ | |a 0936-6555 |2 ISSN |
| 024 | 7 | _ | |a 1433-2981 |2 ISSN |
| 024 | 7 | _ | |a 1433-2987 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2025-02357 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Valentini, C. |b 0 |
| 245 | _ | _ | |a Haematotoxicity of Craniospinal Radiochemotherapy for Metastatic Paediatric High-Grade Glioma. |
| 260 | _ | _ | |a [Erscheinungsort nicht ermittelbar] |c 2025 |b Saunders |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1762863371_2808954 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Paediatric high-grade gliomas (pedHGGs) have a dismal prognosis, often characterised by early and diffuse disease progression. Novel treatment approaches are urgently needed to improve outcomes. The upcoming SIOPE-HGG (High Grade Glioma)-01 trial will investigate upfront craniospinal radiochemotherapy (CSI-RCT) for newly diagnosed, nonmetastatic diffuse midline glioma/diffuse intrinsic pontine glioma (DMG/DIPG). As CSI-RCT is frequently avoided due to concerns over haematotoxicity, real-world feasibility data are critically needed.We retrospectively assessed haematological toxicity in 19 patients (aged 3-21 years) with metastatic pedHGG treated with CSI-RCT within the hirn tumor glioblastoma trial (HIT-HGG) and hospital in trial-glioblastoma (HIT-GBM) trial programmes (2002-2024). All patients received craniospinal irradiation (median dose: 35.2 Gy) using photon- or proton-based techniques, with concurrent chemotherapy: temozolomide (TMZ; n = 14) or PEI (cisplatin, etoposide, ifosfamide; n = 5). Haematological toxicities were graded according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0.Grade 3 to 4 haematotoxicity was observed in 7 of 19 patients (36.8%). Chemotherapy was discontinued in two cases-one due to TMZ-induced aplastic anaemia (TIAA) and another due to thrombocytopaenia. The remaining patients tolerated full-dose CSI-RCT with manageable side effects, and no unplanned radiotherapy interruptions occurred. The haematotoxicity rate was comparable to or lower than previous reports, indicating that CSI-RCT is feasible with appropriate monitoring and management.This is the largest cohort to date assessing haematological toxicity of upfront CSI-RCT in metastatic pedHGG. Despite notable haematotoxicity, treatment was largely feasible and well-tolerated. These findings support the integration of CSI-RCT into future clinical trials for newly diagnosed DMG/DIPG and provide a foundation for the upcoming SIOPE HGG-01 trial. Proton therapy may further reduce toxicity and warrants prospective evaluation. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Craniospinal radiochemotherapy |2 Other |
| 650 | _ | 7 | |a haematotoxicity |2 Other |
| 650 | _ | 7 | |a paediatric high-grade glioma |2 Other |
| 700 | 1 | _ | |a Perwein, T. |b 1 |
| 700 | 1 | _ | |a Bison, B. |b 2 |
| 700 | 1 | _ | |a Gielen, G. H. |b 3 |
| 700 | 1 | _ | |a Knerlich-Lukoschus, F. |b 4 |
| 700 | 1 | _ | |a Bock, H. C. |b 5 |
| 700 | 1 | _ | |a Seidel, C. |b 6 |
| 700 | 1 | _ | |a Kortmann, R. D. |b 7 |
| 700 | 1 | _ | |a Sturm, D. |0 P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807 |b 8 |u dkfz |
| 700 | 1 | _ | |a Benesch, M. |b 9 |
| 700 | 1 | _ | |a Nussbaumer, G. |b 10 |
| 700 | 1 | _ | |a Krischer, J. M. |b 11 |
| 700 | 1 | _ | |a V Bueren, A. |b 12 |
| 700 | 1 | _ | |a Eyrich, M. |b 13 |
| 700 | 1 | _ | |a Friker, L. L. |b 14 |
| 700 | 1 | _ | |a Hoffmann, M. |b 15 |
| 700 | 1 | _ | |a Gkika, E. |b 16 |
| 700 | 1 | _ | |a Wittig-Sauerwein, A. |b 17 |
| 700 | 1 | _ | |a Hörner-Rieber, J. |b 18 |
| 700 | 1 | _ | |a Schwarz, R. |b 19 |
| 700 | 1 | _ | |a Jablonska, K. |b 20 |
| 700 | 1 | _ | |a Hoffmann, W. |b 21 |
| 700 | 1 | _ | |a Vordermark, D. |b 22 |
| 700 | 1 | _ | |a Rieken, S. |b 23 |
| 700 | 1 | _ | |a Höng, L. |b 24 |
| 700 | 1 | _ | |a Rödel, C. |b 25 |
| 700 | 1 | _ | |a Timmermann, B. |0 P:(DE-HGF)0 |b 26 |
| 700 | 1 | _ | |a Fennell, J. T. |b 27 |
| 700 | 1 | _ | |a Claviez, A. |b 28 |
| 700 | 1 | _ | |a Karremann, M. |b 29 |
| 700 | 1 | _ | |a Kramm, C. M. |b 30 |
| 700 | 1 | _ | |a Krause, M. |0 P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9 |b 31 |u dkfz |
| 773 | _ | _ | |a 10.1016/j.clon.2025.103956 |g Vol. 48, p. 103956 - |0 PERI:(DE-600)1458892-4 |p 103956 |t Clinical oncology |v 48 |y 2025 |x 0936-6555 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:305734 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 26 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 31 |6 P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-12 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-12 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CLIN ONCOL-UK : 2022 |d 2024-12-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-12 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-12 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2024-12-12 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)ED01-20160331 |k ED01 |l DKTK Koordinierungsstelle Essen/Düsseldorf |x 2 |
| 920 | 1 | _ | |0 I:(DE-He78)DD01-20160331 |k DD01 |l DKTK Koordinierungsstelle Dresden |x 3 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)ED01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)DD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|